Efficacy of eribulin in breast cancer: a short report on the emerging new data
Open Access
- 1 February 2017
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 773-779
Abstract
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.Keywords
This publication has 39 references indexed in Scilit:
- Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast CancerClinical Breast Cancer, 2016
- Eribulin targets a ch-TOG-dependent directed migration of cancer cellsOncotarget, 2015
- Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter studyBMC Cancer, 2015
- Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9Breast Cancer Research and Treatment, 2015
- Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteinsProceedings of the National Academy of Sciences, 2015
- Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast CancerClinical Breast Cancer, 2014
- Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational StudyJournal of Cancer, 2014
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing ConditionsCancer Research, 2011
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMolecular Cancer Therapeutics, 2008